Cannara Biotech Stock Fundamentals
| LOVE Stock | CAD 0.75 0.05 6.25% |
Cannara Biotech fundamentals help investors to digest information that contributes to Cannara Biotech's financial success or failures. It also enables traders to predict the movement of Cannara Stock. The fundamental analysis module provides a way to measure Cannara Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cannara Biotech stock.
At this time, Cannara Biotech's Reconciled Depreciation is fairly stable compared to the past year. Income Before Tax is likely to climb to about 8.4 M in 2024, whereas Interest Income is likely to drop slightly above 181 K in 2024. Cannara | Select Account or Indicator |
Cannara Biotech Company Return On Asset Analysis
Cannara Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Cannara Biotech Return On Asset | 0.0378 |
Most of Cannara Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cannara Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Cannara Biotech is extremely important. It helps to project a fair market value of Cannara Stock properly, considering its historical fundamentals such as Return On Asset. Since Cannara Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cannara Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cannara Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Cannara Total Assets
Total Assets |
|
Based on the latest financial disclosure, Cannara Biotech has a Return On Asset of 0.0378. This is 100.43% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all Canada stocks is 127.0% lower than that of the firm.
Cannara Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cannara Biotech's current stock value. Our valuation model uses many indicators to compare Cannara Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannara Biotech competition to find correlations between indicators driving Cannara Biotech's intrinsic value. More Info.Cannara Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.56 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cannara Biotech is roughly 1.79 . At this time, Cannara Biotech's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cannara Biotech's earnings, one of the primary drivers of an investment's value.Cannara Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in return on asset category among its peers.
Cannara Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cannara Biotech from analyzing Cannara Biotech's financial statements. These drivers represent accounts that assess Cannara Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cannara Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 67.8M | 130.1M | 118.4M | 61.2M | 70.4M | 128.1M | |
| Enterprise Value | 72.9M | 142.8M | 154.6M | 103.0M | 118.4M | 143.2M |
Cannara Fundamentals
| Return On Equity | 0.0678 | ||||
| Return On Asset | 0.0378 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 113.72 M | ||||
| Shares Outstanding | 90.02 M | ||||
| Shares Owned By Insiders | 49.42 % | ||||
| Number Of Shares Shorted | 10 | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 57.26 M | ||||
| Gross Profit | 17.33 M | ||||
| EBITDA | 14.29 M | ||||
| Net Income | 6.95 M | ||||
| Cash And Equivalents | 5.56 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 5.97 M | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 2.95 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | 5.44 M | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | 0.07 X | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 72.02 M | ||||
| Total Asset | 141.52 M | ||||
| Retained Earnings | (19.34 M) | ||||
| Working Capital | 30.51 M | ||||
| Net Asset | 141.52 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 65.8 M | 69.1 M | |
| Cost Of Revenue | 34.5 M | 36.3 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.16 | 0.15 | |
| Research And Ddevelopement To Revenue | 0.01 | 0.01 | |
| Capex To Revenue | 0.09 | 0.09 | |
| Revenue Per Share | 0.91 | 0.95 | |
| Ebit Per Revenue | 0.12 | 0.13 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.